Keeran Sampat, MD
Hematology & Oncology · Arlington, VANPI 1518103811
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,960 of the $13,357 with a category attached, or 82.1%. 19 manufacturers reported payments, led by Bayer at 40.9% of the total. Reporting peaked in 2019 at $10,296 and has fallen 95.3% since, to $488 in 2025. Among hematology & oncology clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 54 payments — averaging $247.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$5K
- Bristol Myers Squibb$3K
- Johnson & Johnson$2K
- Ipsen Biopharmaceuticals, Inc$2K
- Boston Scientific$471
- AstraZeneca$151
- plus $665 from 13 others
Across 67 payments — averaging $7581.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ipsen Bioscience Inc.$222K
- Janssen Research & Development, LLC$137K
- Genentech, Inc.$57K
- AstraZeneca$43K
- Coherus Oncology, Inc.$29K
- AbbVie$18K
- plus $3K from 1 others
What the payments were for
- Consulting fees$10,96082%
- Travel & lodging$5914%
- Food & beverage$1,80614%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 13 | $5,465 |
| Bristol Myers Squibb | 6 | $2,629 |
| Johnson & Johnson | 4 | $2,250 |
| Ipsen Biopharmaceuticals, Inc | 1 | $1,725 |
| Boston Scientific | 4 | $471 |
| AstraZeneca | 4 | $151 |
| Myriad Genetic Laboratories, Inc. | 1 | $130 |
| Novartis | 6 | $130 |
| Dilon Technologies, Inc. | 1 | $100 |
| Daiichi Sankyo Inc. | 3 | $60 |
| Pfizer | 2 | $53 |
| Merck | 2 | $41 |
| Rigel Pharmaceuticals, Inc. | 1 | $26 |
| Pharmacosmos Therapeutics Inc. | 1 | $26 |
| Pharmaessentia USA Corporation | 1 | $24 |
| Array Biopharma Inc | 1 | $22 |
| Astellas Pharma US Inc | 1 | $21 |
| Seagen Inc. | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Nexavar$5,215
- Luspatercept$2,435
- Erleada$2,214
- ONIVYDE$1,725
- TheraSphere Y90 Glass Microspheres 10 GBq$405
- myRisk$130
How this compares
$13,357 in reported general payments places this provider in the 90th percentile of 293 hematology & oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 29 | $316,508 |
| PomalystPomalidomide | 12 | $282,835 |
| JakafiRuxolitinib Phosphate | 22 | $270,214 |
| TasignaNilotinib Hcl | 11 | $253,794 |
| XtandiEnzalutamide | 15 | $238,538 |
| CalquenceAcalabrutinib Maleate | 11 | $169,661 |
| PromactaEltrombopag Olamine | 21 | $164,451 |
| GleevecImatinib Mesylate | 12 | $119,040 |
| Abiraterone Acetate | 68 | $72,304 |
| Imatinib Mesylate | 21 | $50,206 |
| EliquisApixaban | 51 | $29,493 |
| XareltoRivaroxaban | 32 | $21,754 |
| Acyclovir | 55 | $846 |
| Hydroxyurea | 42 | $713 |
| Prochlorperazine Maleate | 45 | $393 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisTasigna, Promacta, Gleevec | $130 | $537,28444 claims |
| Astellas Pharma US IncXtandi | $21 | $238,53815 claims |
| AstraZenecaCalquence | $151 | $169,66111 claims |
| PfizerEliquis | $53 | $29,49351 claims |
| Johnson & JohnsonXarelto | $2,250 | $21,75432 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 293 hematology & oncology providers in Virginia.
Other hematology & oncology in Arlington
- Ruby KochharHampton$236K
- Victor YazbeckRichmond$190K
- David ChangNewport News$141K
- William ErshlerFairfax$139K
- Yue ZhangVirginia Beach$105K
- Jerome GoldschmidtChristiansburg$105K
- Attique SamdaniRichmond$104K
- Gary SimmonsNorfolk$82K
- Mark FlemingHampton$71K
- Sekwon JangFairfax$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.